Breast Cancer

Celldex Completes Accrual of CDX-011 Phase 2b "EMERGE" Study in Advanced Breast Cancer

Published in Women's Health Weekly, January 5th, 2012

2012 JAN 5 -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced that it has completed accrual of the EMERGE study, a randomized Phase 2b study evaluating CDX-011 (glembatumumab vedotin) in patients with previously treated metastatic or locally advanced breast cancer. The Company anticipates presenting results at an appropriate scientific conference in the first half of 2012.

"The median survival of patients with metastatic breast cancer is two to three years and for patients with "triple-negative" disease, the prognosis is even more grim," said Thomas Davis, MD, Chief Medical Officer of Celldex Therapeutics. "A previous Phase 1/2 single arm study of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2012-01-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry